Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5879125 | 1.00 | SLC6A3 (0.49) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL5879124 | 1.00 | SLC6A3 (0.49) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL7503177 | 0.88 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL7492398 | 0.87 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL297013 | 0.87 | SLC6A3 (0.50) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL8067450 | 0.84 | ALDH1A1 (0.43) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL8067451 | 0.84 | ALDH1A1 (0.43) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL9045383 | 0.83 | ALDH1A1 (0.43) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL623726 | 0.82 | SLC6A2 (0.44) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL5879216 | 0.82 | CYP2C19 (0.60) | SLC6A3SLC6A2SLC6A4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-8796268-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796271-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796271-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796271-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2012021696-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021696-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-7034056-B2 | Aryl and biaryl compounds having MCH modulatory activity | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1370520-A1 | ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-0680962-B1 | Heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-20030092715-A1 | Aryl and biaryl compounds having MCH modulatory activity | SCHERING CORPORATION | 2003-05-15 | — | — | US | disclosed |
| WO-2002076929-A1 | ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-5739149-A | TREATING ASTHMA | ZENECA LIMITED (GB) | 1998-04-14 | — | — | US | disclosed |
| US-5635509-A | ASTHMA; BRONCHODILATOR AGENTS; VASODILATION MICROVASCULAR PERMEABILITY; MAST CELLS | ZENECA LIMITED (GB) | 1997-06-03 | — | — | US | disclosed |
| EP-0680962-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | PIK3R1, PIK3R2, PIK3R3 | SLC6A3 4105/4885SLC6A2 4260/4885SLC6A4 4541/4885 |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | PIK3R1, PIK3R2, PIK3R3 | SLC6A3 4292/4885SLC6A2 4318/4885SLC6A4 4566/4885 |
| US-20030092715-A1 | Aryl and biaryl compounds having MCH modulatory activity | MCHR1, MCHR2, MC3R | SLC6A3 889/4885SLC6A2 641/4885SLC6A4 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.